Objective:

To provide comprehensive insights into the digital pathology market and assist healthcare providers in making informed technology purchasing decisions.

Key Findings:

• Only 15% of US healthcare providers have adopted digital pathology, with most using it minimally.
• European countries have higher adoption rates, exceeding 50%, with specific examples of leading countries.
• KLAS reports provide independent benchmarking data on major vendors in the US market, including specific vendor names.

Interpretation:

The digital pathology market is still in its infancy in the US, with significant growth potential but also considerable challenges related to adoption, implementation, and user resistance.

Limitations:

• The report may not cover all vendors or capture every aspect of user experience, and user feedback may vary based on their level of experience with digital pathology.
• Adoption barriers are complex and vary by institution.

Conclusion:

KLAS reports serve as a valuable resource for labs considering digital pathology, helping them navigate vendor options and implementation challenges while addressing the credibility gap between vendor claims and real-world performance.